Risk factors associated with hypogammaglobulinemia in patients treated with 2rituximab for autoimmune disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00037825

Enrollment

511

Registered

2025-09-01

Start date

2025-07-29

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rituximab-associates side effects.

Interventions

Group 1: The study includes data from all individuals aged 18 years or older who received at least one dose of the anti-CD20 monoclonal antibody rituximab for autoimmune diseases between June 1, 2002,

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients who received at least one dose of the anti-CD20 monoclonal antibody rituximab for autoimmune diseases between June 1, 2002, and June 1, 2022, and presented with median serum IgG levels > 700 mg/dl within the year preceding their first rituximab treatment.

Exclusion criteria

Exclusion criteria: Patients treated for oncological diseases and those with incomplete Rituximab dosing documentation were excluded.

Design outcomes

Primary

Measure	Time frame
Time from rituximab application to occurrence of hypogammaglobulinemia (first serum IgG level = 700 mg/dl).	—

Countries

Germany

Contacts

Public ContactThomas Welte

Universitätsklinikum Freiburg

thomas.welte@uniklinik-freiburg.de+4976127033470

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026